Subscription model for new antibiotics: fighting superbugs and drug resistance.
This Act establishes a novel subscription-based funding model to accelerate the development of new antimicrobial drugs targeting critical infections and drug resistance. The government will pay developers a fixed fee (between $750 million and $3 billion per contract) for access to these drugs, decoupling company revenue from sales volume. This aims to ensure a stable supply of life-saving treatments and enhance public health security against emerging superbugs.
Key points
Funding for Innovation: Allocates $6 billion to establish subscription contracts for companies developing critically needed antimicrobial drugs to combat resistance.
Guaranteed Supply: Companies receiving contracts must ensure continuous commercial availability and a reliable supply chain of the drug in the U.S.
Promoting Responsible Use: Creates grant programs for healthcare facilities to support judicious antimicrobial use, surveillance, and resistance monitoring.
Contract Value: Subscription contracts range from $750 million to $3 billion, adjusted based on the drug's favorable characteristics, such as treating multi-drug-resistant infections or having a novel mechanism.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.